{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.1","upperLimit":"67.1","value":"51.2"},{"groupId":"OG001","lowerLimit":"20.2","upperLimit":"59.4","value":"38.5"},{"groupId":"OG002","lowerLimit":"47.6","upperLimit":"84.1","value":"67.9"},{"groupId":"OG003","lowerLimit":"66.3","upperLimit":"95.8","value":"85.2"},{"groupId":"OG004","lowerLimit":"29.1","upperLimit":"70.9","value":"50.0"},{"groupId":"OG005","lowerLimit":"65.1","upperLimit":"95.6","value":"84.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"26"}],"units":"Participants"}],"description":"Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. Participants who do not have any postbaseline tumor response assessments for any reason were considered.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Gastric-GEJ cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort A.\n\nParticipants with Gastric-GEJ cancer (Second-Third L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle in Cohort B.","id":"OG000","title":"Cohort A and B"},{"description":"Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG001","title":"Cohort A1"},{"description":"Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG002","title":"Cohort A2"},{"description":"Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG003","title":"Cohort C"},{"description":"Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG004","title":"Cohort D"},{"description":"Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG005","title":"Cohort E"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received at least one dose of the study drug. Per Protocol, Cohort A and B participants \\[Gastric-GEJ cancer (Second-Third L)\\] were combined and outcome data was analyzed under a single arm (Cohort A and B).","reportingStatus":"POSTED","timeFrame":"Baseline to Measured Progressive Disease (Up to 24 Months)","title":"Phase 1a and 1b: Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]","type":"SECONDARY","unitOfMeasure":"percentage of participants"}